

ZIX CORP  
Form 8-K  
December 08, 2009

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported):**

**December 3, 2009**

**ZIX CORPORATION**

**(Exact name of registrant as specified in its charter)**

**Texas**  
**(State or other jurisdiction of  
incorporation)**

**0-17995**  
**(Commission File Number)**

**75-2216818**  
**(IRS Employer Identification No.)**

**2711 North Haskell Avenue**  
**Suite 2200, LB 36**  
**Dallas, Texas 75204-2960**

**(Address of principal executive offices) (Zip Code)**

**Registrant's telephone number, including area code: (214) 370-2000**

**Not Applicable**

**(Former name or former address, if changed since last report.)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 2.05 Costs Associated with Exit or Disposal Activities.**

On December 3, 2009, the Board of Directors of Zix Corporation (the Company) completed an ongoing review of strategic alternatives for the Company's e-Prescribing business and concluded that the Company should exit this business by winding down its operations while honoring ongoing contractual obligations to customers and others. On December 8, 2009, the Company issued a press release announcing its intent to exit the e-Prescribing business. A copy of this press release is attached hereto as Exhibit 99.1. At this time, the Company is unable to make a determination of the estimated costs and cash expenditures associated with winding down the e-Prescribing business, as required by this Item of Form 8-K. Once this determination has been made, the Company will file an amended report on Form 8-K/A and include such information under Item 2.05.

Exhibit No. Description

99.1 Press Release, dated December 8, 2009, titled "Zix Corporation Announces Planned Exit from e-Prescribing Business".

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ZIX CORPORATION  
(Registrant)

Date: December 8, 2009

By: /s/ Susan K. Conner  
Susan K. Conner  
Chief Financial Officer

---

INDEX TO EXHIBITS

Exhibit No.	Description
99.1	Press Release, dated December 8, 2009, titled Zix Corporation Announces Planned Exit from e-Prescribing Business.